Alterome leverages its Kraken structure-guided, machine-learning drug discovery platform to design mutation-selective and isoform-selective small-molecule therapies. Its preclinical pipeline features a covalent AKT1 E17K mutation-selective inhibitor and a KRAS isoform-selective inhibitor designed to address approximately 90% of KRAS mutations, including G12V and G12D. The company emphasizes precision approaches intended to target cancer cells over normal cells to increase inhibition of key drivers while improving safety. Alterome recently closed a $132 million Series B financing to advance multiple wholly owned programs. Proceeds will be used to support advancing lead programs into the clinic, with the AKT1 and KRAS programs expected to begin clinical testing within the next 12 months. The company is led by an experienced precision oncology R&D team and is based in San Diego. Alterome Therapeutics is a precision oncology biotech developing alteration-specific targeted therapies to treat cancer. The company designs its pipeline programs using an in-house computational chemistry platform called “The Kraken,” which provides atomic-level insights and predicts ligand activity and binding modes. Its current pipeline comprises three next-generation precision oncology programs that the company plans to advance with the new financing. Management emphasizes a blend of computational chemistry, medicinal chemistry, and translational biology to design highly selective therapeutics against validated oncogenic drivers. The company is led by founder, CEO and CSO Eric Murphy, Ph.D., and an R&D team with experience in developing marketed oncology small-molecule drugs. Financially, Alterome has raised nearly $100 million to date following the latest extension to its Series A. Alterome Therapeutics is a precision oncology biotechnology company focused on developing alteration-specific therapeutics that target high-value, validated oncogenic drivers. The company is building targeted, alteration-specific medicines intended to advance the precision oncology field and transform treatment paradigms for cancer patients. Leadership is headed by co-founder Eric Murphy, Ph.D., who will serve as chief executive and chief scientific officer, and co-founder Ryan Corcoran, M.D., Ph.D., who will serve on the board and scientific advisory board. The team emphasizes seasoned R&D leaders with a history of developing marketed oncology small-molecule drugs. Alterome positions its scientific approach to address validated oncogenic drivers and pursue precision-targeted cancer therapies.

Total raised

$231M

Funding rounds

3

Latest round

Series B

Latest activity

Apr 2024